Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
Financial Services
$10.38 +0.91%
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
52W Low $11.00High $16.75
Volume 1.05M
Average 0.55M
Income Statement
Follow revenue through to earnings.
Revenue
$31.89M
FY 2025 · Annual
+55.9% YoYOperating Income
-$235.06M
FY 2025 · Annual
Net Income
-$203.15M
FY 2025 · Annual
Income Statement
USD
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| 127.45M | 50.09M | |
| 127.45M | 50.09M |
GENB Earnings Waterfall · TTM
NASDAQ:GENB · Revenue to Net Income
No earnings data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 3, 2026 |
How much revenue does GENB generate?
Generate Biomedicines, Inc. (GENB) reported $31.89M of revenue in fiscal 2025.
Is GENB profitable?
Generate Biomedicines, Inc. (GENB) reported -$203.15M of net income, with a net margin of -637.0%.
Continue the stock analysis
Jump to another research area for this company.